

Answering reviewers

All the correction required were performed.

The text and tables were revised by [bpg@filipodia.com](mailto:bpg@filipodia.com).

In the reviewed text locked for submission received by filipodia the authors included the self-certifications:

- Biostatistics Review Certificate
- Clinical Trial Registration Statement
- Conflict-of-Interest Disclosure Form
- Signed Informed Consent Form(s) or Document(s)
- Institutional Review Board Approval Form or Document
- CONSORT 2010 Statement

Dear Reviewers and Editors,

The assertion "I am uncertain if there are any studies necessitating follow-up for a decade" is deemed unjust. Firstly, minimal follow-up is acknowledged and should consistently be disclosed as a limitation in the pertinent section of any manuscript, and in the future perspectives section of articles, emphasis is often placed on studies with extensive follow-up periods. Secondly, this necessity is even more pronounced for research concerning a device that has undergone phase 3 trials and, due to economic and circumstantial factors rather than clinical rationale, has been designated for application in aesthetic medicine owing to its efficacy in that domain and significantly higher remuneration. Moreover, a study examining the long-term outcomes of collagenase is particularly imperative at this juncture, given the impending expiration of Xiapex's patent and the potential for other pharmaceutical companies to produce and re-market it for Dupuytren's disease. Additionally, considering the burgeoning interest in collagenases with numerous products under development, an investigation into the long-term effects of collagenase is of utmost importance.

Rome 13/03/2024



Roberto De Vitis